
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Bio-Techne Corp (TECH)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TECH (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $64.15
1 Year Target Price $64.15
7 | Strong Buy |
3 | Buy |
5 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.04% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.42B USD | Price to earnings Ratio 116.83 | 1Y Target Price 64.15 |
Price to earnings Ratio 116.83 | 1Y Target Price 64.15 | ||
Volume (30-day avg) 15 | Beta 1.39 | 52 Weeks Range 45.94 - 80.64 | Updated Date 08/15/2025 |
52 Weeks Range 45.94 - 80.64 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.5 | Actual 0.53 |
Profitability
Profit Margin 6.02% | Operating Margin (TTM) -3.64% |
Management Effectiveness
Return on Assets (TTM) 2.92% | Return on Equity (TTM) 3.68% |
Valuation
Trailing PE 116.83 | Forward PE 26.53 | Enterprise Value 8858610709 | Price to Sales(TTM) 6.91 |
Enterprise Value 8858610709 | Price to Sales(TTM) 6.91 | ||
Enterprise Value to Revenue 7.26 | Enterprise Value to EBITDA 41.75 | Shares Outstanding 156767008 | Shares Floating 153078830 |
Shares Outstanding 156767008 | Shares Floating 153078830 | ||
Percent Insiders 1.08 | Percent Institutions 101.68 |
Upturn AI SWOT
Bio-Techne Corp

Company Overview
History and Background
Bio-Techne Corp. was founded in 1981. Initially focused on producing recombinant proteins, the company expanded through acquisitions and organic growth to offer a broader range of products and services for the life science industry.
Core Business Areas
- Protein Sciences: Develops and manufactures recombinant and native proteins, antibodies, immunoassays, and related reagents.
- Diagnostics and Genomics: Offers molecular controls, reagents, instruments, and targeted DNA/RNA sequencing solutions for diagnostics.
- Cell and Gene Therapy: Provides tools and technologies for cell culture, cell activation, gene editing, and cell therapy manufacturing.
Leadership and Structure
Charles Kummeth is the President and CEO. The company has a functional organizational structure with divisions based on product lines and services, overseen by a board of directors.
Top Products and Market Share
Key Offerings
- Proteins & Reagents: A wide range of recombinant proteins, antibodies, and chemical products essential for research. Competitors include Thermo Fisher Scientific and Merck. Market share and revenue per product are not publicly disclosed with enough granularity to be accurate; however, this segment contributes substantially to overall revenue.
- Exosome Diagnostics: Develops liquid biopsy tests for cancer diagnosis and monitoring. Competitors include Qiagen and Roche. Market share data is not publicly available, but this area has high growth potential.
- Advanced Cell Diagnostics (ACD): RNAscopeu00ae and BaseScopeu2122 platforms for in situ hybridization assays. Competitors include Qiagen and Danaher's Leica Biosystems. Market share is not specifically disclosed, but it's a key driver of growth.
Market Dynamics
Industry Overview
The life science tools and diagnostics industry is experiencing growth driven by increasing research funding, advancements in genomics and proteomics, and the development of personalized medicine. The industry is characterized by intense competition and technological innovation.
Positioning
Bio-Techne Corp. holds a strong position in the protein sciences and cell and gene therapy markets, with a reputation for high-quality products and innovative technologies. Their competitive advantage lies in their diverse product portfolio and strong brand recognition.
Total Addressable Market (TAM)
The global life science tools market is estimated to be over $100 billion. Bio-Techne is positioned to capture a significant portion of this TAM through its diversified product offerings and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong brand reputation
- Focus on high-growth markets (cell and gene therapy)
- Established customer base
- Strategic acquisitions
Weaknesses
- High reliance on research funding
- Integration risks associated with acquisitions
- Competition from larger players
- Relatively smaller size compared to some competitors
Opportunities
- Expanding into emerging markets
- Developing new diagnostic and therapeutic tools
- Capitalizing on the growth of personalized medicine
- Leveraging data analytics to improve product development
- Growth in Cell and Gene Therapy Market
Threats
- Economic downturns affecting research funding
- Intense competition
- Regulatory changes impacting diagnostic products
- Technological obsolescence
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- TMO
- DHR
- ILMN
- WAT
Competitive Landscape
Bio-Techne faces competition from larger, more diversified companies with greater resources. However, Bio-Techne's focus on specific niches and its reputation for quality give it a competitive advantage. The competitive landscape includes companies specializing in life science tools, diagnostics, and biopharmaceuticals.
Major Acquisitions
Asuragen
- Year: 2019
- Acquisition Price (USD millions): 320
- Strategic Rationale: Expanded Bio-Techne's molecular diagnostics portfolio and capabilities.
Growth Trajectory and Initiatives
Historical Growth: Bio-Techne has demonstrated consistent growth over the past decade, driven by organic growth and strategic acquisitions. The company's focus on high-growth markets, such as cell and gene therapy, has contributed to its success.
Future Projections: Analysts predict continued growth for Bio-Techne, driven by increasing demand for life science tools and diagnostics. Growth rate forecasts vary depending on market conditions and company performance.
Recent Initiatives: Recent initiatives include acquisitions of companies specializing in cell and gene therapy, expansion of product offerings, and investments in R&D.
Summary
Bio-Techne is a well-positioned player in the life science tools and diagnostics market, particularly with its focus on high-growth areas like cell and gene therapy. Strategic acquisitions and a strong product portfolio have fueled growth, but competition from larger players remains a significant challenge. The company's success hinges on continued innovation and effective integration of acquired businesses. Monitoring economic trends and adapting to regulatory changes are also crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on available estimates and may not be precise. Financial data should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Techne Corp
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3100 | Website https://www.bio-techne.com |
Full time employees 3100 | Website https://www.bio-techne.com |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.